Development Stage: The drug is moving into Phase 3 trials (ENLIGHTEN-1) as of early 2026 Ongoing Studies: Beyond weight loss, studies are investigating its use for obesity-related conditions such as obstructive sleep apnea (ENLIGHTEN-3) and knee osteoarthritis
BPC-157 works best as part of a broader plan that includes hormone evaluation, nutrition support, and activity adjustments
These drugs can be expensive, topping $1,000 per month without insurance
This product aligns with the following standards: Research & Classification Notice This product is intended exclusively for laboratory research
Our Liposomal Glutathione is designed to reach the areas where it can actually do its work, including the liver and the melanocytes in your skin
This provides a clear label that identifies the product as a dietary supplement, which builds immediate trust with the security staff